COHBAR INC (CWBR)       1.71  -0.05 (-2.84%)

1.71  -0.05 (-2.84%)

US19249J3077 - Common Stock

COHBAR INC1.71

NASDAQ:CWBR (12/6/2022, 7:00:01 PM)-0.05 (-2.84%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-08 2022-11-08/amc Earnings (Next) 03-27 2023-03-27
Ins Owners 7.17% Inst Owners 0.3%
Market Cap 4.97M Shares 2.91M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 82.86
IPO 01-06 2015-01-06

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CWBR Daily chart

Company Profile

CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. The company is headquartered in Menlo Park, California and currently employs 9 full-time employees. The company went IPO on 2015-01-06. The firm focuses on developing therapeutics targeting chronic and age-related diseases. The company is advancing a pipeline of peptide analogs through varying stages of development, such as CB5138-3 for idiopathic pulmonary fibrosis (IPF); CB4211 for the treatment of non-alcoholic steatohepatitis (NASH) and obesity; and several preclinical and discovery-stage programs. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing, and optimizing analogs of these natural mitochondrial derived peptides (MDPs), as well as developing and conducting screens to identify and characterize the activities of these peptides are referred to its Mito+ platform. The company is using its Mito+ platform to identify and develop modified versions of natural peptides called analogs, to treat a range of serious conditions, with a focus on chronic diseases involving inflammation and fibrosis.

Company Info

COHBAR INC

1455 Adams Drive, Suite 2050

Menlo Park CALIFORNIA 94025

P: 16504467888.0

CEO: Steven Engle

Employees: 9

Website: https://www.cohbar.com/

CWBR News

News Imagea month ago - CohBar, Inc.CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

Conference call and webcast today at 5:00 p.m. ET, November 8, 2022

News Imagea month ago - CohBar, Inc.CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

Conference call and webcast today at 5:00 p.m. ET, November 8, 2022...

News Imagea month ago - CohBar, Inc.CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022

Company to host conference call and webcast at 5:00 p.m. ET

News Imagea month ago - CohBar, Inc.CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022

Company to host conference call and webcast at 5:00 p.m. ET...

News Image2 months ago - InvestorPlace7 Nasdaq Stocks to Sell Before They Die

With more pain ahead for equities, these seven Nasdaq stocks should be the first to be expelled from investors' portfolios.

News Image3 months ago - CohBar, Inc.CohBar Announces Reverse Stock Split

MENLO PARK, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the...

CWBR Twits

Here you can normally see the latest stock twits on CWBR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example